Drugs / V526
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00850616 | Apr 2005 → Aug 2006 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V526 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00850616 ↗ |
| Known as | MRKAd5+6 | “0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.” NCT00850616 ↗ |
| Route | Intramuscular | “intramuscular injections of MRKAd5+6 trigene vaccine (V526)” NCT00850616 ↗ |